New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2014
14:48 EDTEWP, TC, MUR, MDCO, SNSSHigh option volume stocks: TC SNSS MUR EWP MDCO
News For TC;SNSS;MUR;EWP;MDCO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
17:33 EDTTCRoyal Gold says received about 26,200 ounces of gold from Mount Milligan mine
Royal Gold (RGLD) announces that its wholly owned subsidiary, RGLD Gold AG, received approximately 26,200 ounces of gold for the quarter ended March 31 from the Mount Milligan mine as part of its purchase and sale agreement with Thompson Creek Metals Company (TC). Royal Gold currently sells most of the delivered gold within three weeks of receipt, and recognizes revenue on its streaming transactions when the metal received is sold. For the quarter ended March 31, Royal Gold sold approximately 24,200 ounces of gold from Thompson Creek, which is a nearly 70% increase over the December quarter. In addition, Royal Gold had approximately 6,800 ounces remaining in inventory as of March 31. At March 31, Royal Gold had one provisionally priced final shipment outstanding, which was the 75% balance on shipment 12. That balance of approximately 5,000 ounces was not received as of March 31, and was not included in inventory. Hereafter, all deliveries to Royal Gold will be based solely on final settlement timing and volumes, subject to Thompson Creek’s smelter contracts, which can take three to five months after concentrate is produced at the mine. The Company notes that Thompson Creek reported production for Mount Milligan of approximately 46,119 ounces of payable gold and sales of approximately 36,750 ounces of payable gold in the quarter ended March 31.
17:05 EDTTCThompson Creek reports Q1 production and sales
Subscribe for More Information
April 15, 2015
17:49 EDTMDCOThe Medicines Co. up 7% after FDA panel backs approval of cangrelor
Subscribe for More Information
17:18 EDTMDCOThe Medicines Co. confirms FDA Advisory Committee backs approval of cangrelor
Subscribe for More Information
15:37 EDTMDCOFDA panel votes in favor of approval for cangrelor
Subscribe for More Information
07:57 EDTMDCOThe FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting
The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link
07:01 EDTMDCOThe Medicines Co. stock trading halted today
Subscribe for More Information
April 13, 2015
11:13 EDTMDCOFDA panel briefing docs look positive for Medicines Co., says Leerink
Subscribe for More Information
10:15 EDTMDCOHigh option volume stocks
Subscribe for More Information
10:00 EDTTCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:29 EDTTCThompson Creek downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
April 10, 2015
07:09 EDTMDCOThe Medicines Co. outlook still upbeat after preannouncement, says RBC Capital
After The Medicines Co preannounced lower than expected Q1 revenue, RBC Capital remains upbeat on the company's outlook, citing what it sees as the success of the company's gram negative franchise, its progress on earlier stage, cardiovascular candidates, and approval of and revenue support from up to four products in the near-term. The firm says the shares are "fundamentally inexpensive," while the company has a number of upcoming catalysts. It trimmed its price target on the shares to $37 from $38 but keeps an Outperform rating on the stock.
06:46 EDTMDCOThe Medicines Co. selloff a buying opportunity, says Leerink
Leerink views the selloff in shares of The Medicines Co. after the company preannounced weaker than expected Q1 revenue as a buying opportunity. The firm expects upcoming pipeline catalysts to create value in 2015. It thinks more visibility into four new products with significant revenue potential will move the stock higher. Leerink believes the preannouncement, driven by hospital customers buying fewer products due to the potential for a generic Angiomax to become available, should not come as a surprise. It keeps an Outperform rating on The Medicines Co.
April 9, 2015
16:32 EDTMDCOThe Medicines Co. down 15% after weaker than expected Q1 guidance
Subscribe for More Information
16:16 EDTMDCOThe Medicines Co. to resume trading at 4:30 pm ET
Subscribe for More Information
16:03 EDTMDCOThe Medicines Co. reports preliminary Q1 revenue $125M-$130M, consensus $184.17M
Subscribe for More Information
16:01 EDTMDCOThe Medicines Co. trading halted, pending news
Subscribe for More Information
April 7, 2015
12:25 EDTSNSSSunesis recommended by Agora Financial's FDA Trader
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use